Coronary Artery Disease: Root Causes Beyond Cholesterol

Introduction: The Cholesterol Myth and the Real Drivers of CAD

Coronary artery disease (CAD) is the leading cause of death worldwide, responsible for approximately 9 million deaths annually. For decades, the dominant narrative has been simple: high LDL cholesterol clogs arteries. Lower LDL, reduce risk. Yet half of all myocardial infarctions occur in people with normal LDL cholesterol — and many patients with dramatically elevated LDL never develop significant CAD.

This paradox is not a mystery. It reflects the incomplete picture painted by standard lipid panels. CAD is a multifactorial inflammatory disease driven by insulin resistance, oxidative stress, homocysteine elevation, lipoprotein(a), endothelial dysfunction, and chronic systemic inflammation — factors that standard cardiovascular workups routinely miss.

What Is Coronary Artery Disease?

CAD is characterized by atherosclerotic plaque buildup within the coronary arteries — the vessels supplying oxygenated blood to the myocardium. As plaques grow, they narrow the coronary lumen (stenosis), reducing blood flow and causing:

• Stable angina: Predictable chest pain with exertion; fixed stenosis limiting flow under demand
• Unstable angina / NSTEMI: Plaque erosion or partial rupture with non-occlusive thrombus
• STEMI: Complete coronary occlusion from plaque rupture and thrombosis; full-thickness myocardial infarction
• Sudden cardiac death: Ventricular fibrillation triggered by ischemia in vulnerable myocardium

Critically, most MIs are caused not by the most stenotic plaques, but by rupture of vulnerable, lipid-rich, inflamed plaques with thin fibrous caps — plaques that may cause only 30–50% stenosis and are invisible to stress testing.

Root Cause 1: Insulin Resistance and Hyperinsulinemia

Insulin resistance is the single most prevalent and underappreciated root cause of CAD. It drives coronary disease through a cascade of interconnected mechanisms:

• Atherogenic dyslipidemia: Insulin resistance drives elevated triglycerides, low HDL, and increased small dense LDL — the most atherogenic lipoprotein subtype
• Endothelial dysfunction: Impaired PI3K/Akt/eNOS signaling reduces nitric oxide production while upregulating endothelin-1 and VCAM-1
• Systemic inflammation: Visceral adiposity secretes TNF-α, IL-6, and resistin, activating NF-κB in vascular tissue
• Prothrombotic state: Insulin resistance elevates fibrinogen, PAI-1, and von Willebrand factor, promoting coronary thrombosis
• Coronary microvascular dysfunction: Insulin resistance impairs coronary microvascular dilation, causing ischemia without obstructive CAD (INOCA)
• Hyperglycemia-driven AGE formation: Advanced glycation end-products cross-link collagen in arterial walls, increasing stiffness and promoting plaque vulnerability

The INTERHEART study — the largest global MI case-control study — identified abdominal obesity and diabetes (both manifestations of insulin resistance) as two of the three most powerful modifiable risk factors for MI, accounting for more attributable risk than LDL cholesterol.

Root Cause 2: Lipoprotein(a) — The Genetic Wildcard

Lipoprotein(a) [Lp(a)] is an LDL-like particle with an additional apolipoprotein(a) [apo(a)] attached via a disulfide bond. It is the most atherogenic lipoprotein and is almost entirely genetically determined — diet and lifestyle have minimal effect on Lp(a) levels.

Lp(a) drives CAD through multiple mechanisms:

• Carries oxidized phospholipids (OxPL) that directly activate endothelial inflammation
• Inhibits plasminogen activation, promoting coronary thrombosis
• Promotes smooth muscle cell proliferation and intimal thickening
• Accelerates aortic valve calcification

Lp(a) >50 mg/dL (or >125 nmol/L) is present in approximately 20% of the population and confers a two- to four-fold increased CAD risk independent of LDL-C. It is not measured on standard lipid panels. Every patient with premature CAD, family history of early heart disease, or treatment-refractory cardiovascular risk should have Lp(a) measured at least once.

Root Cause 3: Homocysteine Elevation

Homocysteine is a sulfur-containing amino acid produced during methionine metabolism. Elevated homocysteine (>10 µmol/L) is an independent CAD risk factor that operates through direct vascular toxicity:

• Damages endothelial cells through oxidative stress and thiol-mediated mechanisms
• Promotes LDL oxidation, accelerating foam cell formation
• Activates smooth muscle cell proliferation and intimal hyperplasia
• Impairs endothelial nitric oxide production
• Creates a prothrombotic environment by activating coagulation factors and impairing fibrinolysis

Homocysteine elevation is driven by B12, folate, and B6 deficiency — and by MTHFR polymorphisms that impair methylation. It is one of the most actionable CAD risk factors: methylated B-vitamin supplementation reliably normalizes homocysteine within weeks. Yet it is absent from standard cardiovascular panels in most clinical settings.

Root Cause 4: Oxidative Stress and oxLDL

As detailed in our atherosclerosis article, oxidized LDL — not total LDL-C — is the primary atherogenic particle in coronary disease. oxLDL is taken up by macrophage scavenger receptors without feedback inhibition, driving foam cell formation and plaque progression. Key drivers of LDL oxidation in CAD:

• Hyperglycemia and AGE formation
• Smoking — the most potent driver of LDL oxidation
• Mitochondrial ROS overproduction from metabolic dysfunction
• Lp(a)-carried oxidized phospholipids
• Heavy metal burden (mercury, lead, cadmium)

Measuring oxLDL and ApoB (total atherogenic particle count) provides far more clinically actionable information than LDL-C alone. A patient with low LDL-C but high oxLDL and high ApoB has a dramatically different risk profile than their standard panel suggests.

Root Cause 5: Chronic Inflammation

The JUPITER trial demonstrated that patients with normal LDL-C but elevated hsCRP (>2 mg/L) had significantly elevated cardiovascular event rates — and that statin therapy reduced events primarily through anti-inflammatory mechanisms, not LDL lowering alone. This finding reframed CAD as fundamentally an inflammatory disease.

Key inflammatory drivers specific to CAD:

• Pericardial and epicardial fat: Directly secretes pro-inflammatory cytokines into coronary adventitia, promoting local plaque inflammation
• Gut dysbiosis and TMAO: Promotes macrophage foam cell formation and coronary plaque vulnerability
• Periodontal disease: P. gingivalis and other oral pathogens have been identified within coronary plaques; periodontal disease doubles CAD risk
• Chronic infections: CMV, H. pylori, and Chlamydia pneumoniae drive coronary inflammation
• Air pollution: Particulate matter (PM2.5) activates endothelial NF-κB and promotes coronary plaque instability

Root Cause 6: Autonomic Dysfunction and Psychosocial Stress

Psychosocial stress is a major and underappreciated CAD risk factor. The INTERHEART study identified psychosocial stress as accounting for 32% of population-attributable MI risk — comparable to smoking. Mechanisms include:

• Chronic sympathetic activation increases heart rate, blood pressure, and coronary vasomotor tone
• Cortisol promotes visceral adiposity, insulin resistance, and endothelial dysfunction
• Catecholamine surges trigger coronary vasospasm and plaque rupture (Takotsubo cardiomyopathy is the extreme manifestation)
• Reduced HRV — a marker of autonomic imbalance — independently predicts coronary events
• Depression and anxiety are associated with 1.5–2x increased CAD risk and dramatically worse post-MI outcomes

Advanced Biomarkers for Root Cause CAD Assessment

• Lp(a) — measure once; genetically determined; critical for risk stratification
• ApoB — total atherogenic particle count; superior to LDL-C
• oxLDL — primary atherogenic particle
• hsCRP — inflammatory burden; target <1 mg/L
• Homocysteine — target <8 µmol/L
• Fasting insulin / HOMA-IR — metabolic root cause
• TMAO — gut-derived atherogenic metabolite
• Small dense LDL particle number (NMR lipoprofile)
• Coronary artery calcium (CAC) score — gold standard for subclinical CAD burden; zero score has excellent negative predictive value
• Coronary CTA with plaque characterization — identifies vulnerable plaque morphology beyond stenosis

Integrative Protocol: Addressing CAD at the Root

Dietary Foundations

• Low-glycemic, insulin-sensitizing diet: The highest-leverage dietary intervention for CAD risk reduction; eliminates the primary metabolic driver
• Mediterranean-style eating: The PREDIMED trial demonstrated 30% reduction in major cardiovascular events with Mediterranean diet supplemented with olive oil or nuts
• Dietary nitrates: Beetroot, arugula, and leafy greens support endothelial NO production and coronary vasodilation
• Eliminate trans fats and seed oils: Primary dietary drivers of LDL oxidation and systemic inflammation

Targeted Supplementation

• Omega-3 fatty acids (EPA/DHA): 2–4 g/day — reduces triglycerides, inflammation, platelet aggregation, and plaque vulnerability; REDUCE-IT trial showed 25% reduction in cardiovascular events with high-dose EPA
• Nattokinase: 2000–4000 FU/day — reduces Lp(a), fibrinolytic activity, plaque regression evidence
• Berberine: 500 mg 2–3x/day — reduces ApoB, improves insulin sensitivity, activates AMPK
• Vitamin K2 (MK-7): 100–200 mcg/day — activates MGP, preventing coronary calcification
• CoQ10 (ubiquinol): 200–300 mg/day — reduces oxLDL, improves endothelial function, essential for statin users
• Methylated B-complex: Normalizes homocysteine; use methylfolate and methylcobalamin in MTHFR variants
• Aged garlic extract: 1200 mg/day — demonstrated coronary plaque regression in RCTs; reduces Lp(a) modestly
• Magnesium glycinate: 300–400 mg/day — reduces coronary vasospasm, improves endothelial function, antiarrhythmic

Lifestyle Interventions

• Zone 2 aerobic exercise: Improves endothelial function, raises HDL, reduces inflammation, promotes coronary collateral development
• Resistance training: Improves insulin sensitivity, reduces visceral adiposity and pericardial fat
• Smoking cessation: Single most impactful modifiable CAD risk factor; risk normalizes within 3–5 years of cessation
• Stress reduction and HRV training: Reduces sympathetic-driven coronary vasomotor dysfunction and plaque rupture risk
• Sleep optimization: Sleep deprivation accelerates coronary plaque progression; target 7–9 hours with OSA treatment if indicated
• Periodontal care: Treat periodontal disease as a cardiovascular risk factor; regular dental hygiene reduces systemic inflammatory burden

Key Takeaways

• Half of all MIs occur in people with normal LDL-C — standard lipid panels miss the most important CAD risk factors
• Insulin resistance, Lp(a), homocysteine, oxLDL, chronic inflammation, and psychosocial stress are the primary root causes of CAD
• Lp(a) should be measured in every patient with CAD, family history of early heart disease, or treatment-refractory risk
• Omega-3s, nattokinase, berberine, K2, CoQ10, and methylated B-vitamins form the core integrative CAD protocol
• Addressing insulin resistance through diet and lifestyle is the single highest-leverage intervention for CAD prevention and stabilization